Summary
This prediction ended on 14.11.16 with a price of €5.59. The BUY prediction by dokem finished with a performance of 8.69%. dokem has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | -6.401% | -6.401% | -65.782% | -84.815% |
iShares Core DAX® | -1.958% | 4.037% | 23.702% | 22.534% |
iShares Nasdaq 100 | 0.272% | 8.670% | 28.181% | 41.859% |
iShares Nikkei 225® | 0.377% | 7.232% | 21.118% | 9.739% |
iShares S&P 500 | 0.370% | 6.511% | 29.221% | 41.850% |
Comments by dokem for this prediction
In the thread Evotec AG diskutieren
dokem stimmt der Buy-Einschätzung von Effzeh zu
dokem stimmt am 02.10.2016 der Buy-Einschätzung von Effzeh mit dem Kursziel 5,91€ zu.Überschrift: Evotec